

THE PREVENT TRIAL

STOPPING LYMPHEDEMA STARTS WITH PREVENT



The results are in.
And they're conclusive.

92%
of patients

with early detection using
L-Dex® and intervention
did not progress to
chronic lymphedema

Final 3-Year Results

"[L-Dex] screening should be a standard approach for prospective breast cancer-related lymphedema surveillance."

— The PREVENT Trial

PREVENT is the largest randomized trial to assess
lymphedema prevention

1,200
Breast Cancer
Patients



10
Centers

including 6 NCCN/NCI
centers across US and AUS



1:1
Randomization


L-Dex vs.
Tape Measure

Significantly Lower Progression to Chronic Lymphedema


with early detection using L-Dex and intervention versus using tape measure.

Primary Endpoint Result

Progression to Chronic Lymphedema L-Dex vs. Tape Measure



Triggers & Intervention L-Dex vs. Tape Measure



L-Dex More Precise and Reliable than Tape Measure

"[L-Dex] is more specific for lymphedema detection than tape measure."

"[L-Dex], as compared to tape measure, provides a more precise identification of patients likely to benefit from an early compression intervention."

— The PREVENT Trial

L-Dex available on SOZO® only from ImpediMed

Non-invasive
Easy to use
Results in less than 30 seconds*

*As tested on Android



REFERENCES

Ridner SH, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. *Lymphatic Research and Biology* 2022.

impedimed.com/prevent